Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for RARE with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 8. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold RARE had net inflows of $1.86 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Cowen Annual Healthcare Conference on Tuesday, March 12, 2019 at 10 a.m. ET in Boston, MA. Tom Kassberg, the company’s Chief Business Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 at 8 a.m. ET in Miami, FL. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.

Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the pricing of its underwritten public offering of 5,072,464 shares of its common stock at a price to the public of $60.00 per share resulting in gross proceeds of $304.3 million, before underwriting discounts. In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 760,869 shares of the company's common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Merrill Lynch, and Cowen are acting as joint book-running managers for the offering.

Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $37,500,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Merrill Lynch and Cowen are acting as joint book-running managers for the offering.

Investing.com – Swiss-based Roche Holding's bumper offer to acquire Spark Therapeutics on Monday propped up the healthcare sector and fueled speculation on Wall Street that more merger activity is in the pipeline for gene therapy stocks.

The Novato, California-based company said it had a loss of $1.73 per share. The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was ...

NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, ...

Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019. Dr. Suliman, Senior Vice President of Corporate Development and Strategy of Theravance Biopharma, Inc., will serve as an independent director to Ultragenyx. “Dr. Suliman joins the Ultragenyx Board at a key time for the company, and her corporate and commercial strategy experience will be a valuable asset as we continue to advance our pipeline and deliver therapies to patients with rare diseases in need of treatment options,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with long-chain fatty acid oxidation disorder. Patients with this disorder are unable to properly break down fatty acids into energy, leading to serious liver, muscle and heart issues. Researchers looked at how Ultragenyx's drug, UX007, affected 75 patients, including 29 from a previous UX007 Phase 2 trial showing that UX007-treated patients had fewer illness-related visits to the hospital and fewer days in the hospital per year. The safety and efficacy study reaffirmed those results, also showing a reduction in the median number of hospital visits and days in the hospital per year among those treated with the drug. Ultragenyx said it is still on track to submit a new drug application for UX007 in mid-2019. Shares of Ultragenyx have gained 22.7% in the year to date through Friday, while the iShares Nasdaq Biotechnology ETF has gained 14.6%. The S&P 500 has gained 6.5%.